There are currently only a few studies that have investigated the predictive value of systemic interleukin and tumor necrosis factor levels for disease progression in AMD, possibly because previous case‐control studies did not find differences in systemic chemokine and interferon levels between AMD patients and controls.183. This evidence concerns the gene TNF and age-related macular degeneration.